Physician profile
Amar A Parikh
NPI 1023163573
$4,925.92
in general payments reported to CMS, 2019-2025
30 companies · $1,394 in 2025
The $1,394 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $527 · 2021: $713 · 2022: $984 · 2023: $347 · 2024: $689 · 2025: $1,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,731 · Education: $380 · Travel and Lodging: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,730.54 |
| Education | $380.08 |
| Travel and Lodging | $318.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $588.66 | 2020-2025 | Acthar, Terlivaz |
| Opko Pharmaceuticals, LLC | $545.93 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $510.65 | 2019-2025 | Veltassa, Korsuva |
| Akebia Therapeutics INC | $456.58 | 2020-2025 | Vafseo, Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $399.57 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $392.59 | 2019-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $364.80 | 2019-2025 | Jynarque, Voyxact |
| Cook Medical LLC | $318.72 | 2025 | Blue Rhino |
| Travere Therapeutics, INC. | $221.78 | 2024-2025 | |
| Ardelyx, INC. | $143.84 | 2023-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.77 | 2024-2025 | Jardiance |
| Amgen INC. | $118.43 | 2019-2023 | Tavneos, Parsabiv |
| Ani Pharmaceuticals, INC. | $110.00 | 2022-2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $93.05 | 2024-2025 | Wegovy, Ozempic |
| Baxter Healthcare | $51.34 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Outset Medical INC | $50.10 | 2025 | |
| Mallinckrodt Enterprises LLC | $49.66 | 2019 | |
| Calliditas Therapeutics US INC. | $44.12 | 2023-2025 | Tarpeyo |
| Beigene USA, INC. | $43.89 | 2024 | Brukinsa |
| Aurinia Pharma U.S., INC. | $38.62 | 2022 | |
| Welch Allyn | $34.73 | 2021 | |
| Novartis Pharmaceuticals Corporation | $34.70 | 2019-2023 | |
| Horizon Therapeutics Plc | $33.34 | 2022-2023 | Krystexxa |
| Progenics Pharmaceuticals, INC. | $27.92 | 2025 | |
| Cormedix INC. | $23.98 | 2024 | Defencath |
| Sumitomo Pharma America, INC. | $21.47 | 2024 | Gemtesa |
| Glaxosmithkline, LLC. | $20.00 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.56 | 2023 | Keveyis |
| Urogen Pharma, INC. | $15.05 | 2025 | |
| Abbvie INC. | $14.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amar Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.